Modus Therapeutics Holding AB (publ) (MODTX.ST)
SEK 1.24
(-2.75%)
SEK 1.24
(-2.75%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -17.89 Million SEK | 2.31% |
| 2022 | -18.32 Million SEK | 11.46% |
| 2021 | -20.69 Million SEK | -243.84% |
| 2020 | -6.01 Million SEK | 86.19% |
| 2019 | -43.57 Million SEK | 12.24% |
| 2018 | -49.65 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -4.73 Million SEK | -52.59% |
| 2024 Q1 | -3.1 Million SEK | 23.67% |
| 2023 Q1 | -17.65 Million SEK | -88.71% |
| 2023 FY | -17.89 Million SEK | 2.31% |
| 2023 Q4 | -4.06 Million SEK | -31.52% |
| 2023 Q3 | -3.09 Million SEK | 34.12% |
| 2023 Q2 | -4.69 Million SEK | 73.41% |
| 2022 Q3 | -2.9 Million SEK | 2.81% |
| 2022 Q1 | -3.06 Million SEK | 75.06% |
| 2022 Q2 | -2.99 Million SEK | 2.38% |
| 2022 FY | -18.32 Million SEK | 11.46% |
| 2022 Q4 | -9.35 Million SEK | -221.73% |
| 2021 FY | -20.69 Million SEK | -243.84% |
| 2021 Q1 | -1.42 Million SEK | -40.14% |
| 2021 Q4 | -12.28 Million SEK | -176.72% |
| 2021 Q3 | -4.44 Million SEK | -75.33% |
| 2021 Q2 | -2.53 Million SEK | -77.38% |
| 2020 Q4 | -1.01 Million SEK | -46.2% |
| 2020 Q1 | -2.6 Million SEK | 0.0% |
| 2020 FY | -6.01 Million SEK | 86.19% |
| 2020 Q3 | -697 Thousand SEK | 58.95% |
| 2020 Q2 | -1.69 Million SEK | 34.82% |
| 2019 FY | -43.57 Million SEK | 12.24% |
| 2018 FY | -49.65 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alzinova AB (publ) | -16.48 Million SEK | -8.598% |
| Amniotics AB (publ) | -30.87 Million SEK | 42.025% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -39.515% |
| BioArctic AB (publ) | 229.24 Million SEK | 107.807% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 96.161% |
| Saniona AB (publ) | -95.81 Million SEK | 81.32% |
| Simris Alg AB (publ) | -37.3 Million SEK | 52.025% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 94.244% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | 15.144% |
| NextCell Pharma AB | -41.95 Million SEK | 57.347% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -9.142% |
| AcouSort AB (publ) | -17.08 Million SEK | -4.728% |
| Active Biotech AB (publ) | -45.8 Million SEK | 60.924% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 92.8% |
| Camurus AB (publ) | 431.44 Million SEK | 104.148% |
| Cantargia AB (publ) | -280.02 Million SEK | 93.609% |
| Genovis AB (publ.) | 61.5 Million SEK | 129.101% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 84.207% |
| Mendus AB (publ) | -101.61 Million SEK | 82.388% |
| Kancera AB (publ) | -64.88 Million SEK | 72.419% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 432.287% |
| LIDDS AB (publ) | -40.2 Million SEK | 55.487% |
| Lipum AB (publ) | -37.17 Million SEK | 51.861% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -47.568% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 247.07% |
| OncoZenge AB (publ) | -15.9 Million SEK | -12.546% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 95.389% |
| Xintela AB (publ) | -54.08 Million SEK | 66.908% |
| Ziccum AB (publ) | -21.41 Million SEK | 16.416% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 51.722% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 90.039% |
| CombiGene AB (publ) | -35.66 Million SEK | 49.82% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 88.214% |
| Intervacc AB (publ) | -102.85 Million SEK | 82.599% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -3986.073% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -8.316% |
| Corline Biomedical AB | -1.8 Million SEK | -889.331% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 89.936% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 68.503% |
| Aptahem AB (publ) | -11.11 Million SEK | -61.048% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 85.458% |
| Fluicell AB (publ) | -26.55 Million SEK | 32.601% |
| Biovica International AB (publ) | -124.82 Million SEK | 85.662% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 57.613% |
| Abliva AB (publ) | -95.5 Million SEK | 81.261% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 94.525% |
| 2cureX AB (publ) | -32.51 Million SEK | 44.963% |
| I-Tech AB | 20.2 Million SEK | 188.586% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 97.848% |
| Cyxone AB (publ) | -22.98 Million SEK | 22.15% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 80.419% |
| Biosergen AB | -27.03 Million SEK | 33.806% |
| Nanologica AB (publ) | -75.15 Million SEK | 76.187% |
| SynAct Pharma AB | -215.81 Million SEK | 91.707% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 59.375% |
| BioInvent International AB (publ) | -330.3 Million SEK | 94.582% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | 24.603% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 92.816% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -80.231% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 83.624% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -53.254% |